Publicaciones en las que colabora con Daniel Ajona Martínez-Polo (27)

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  2. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

  3. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion

    Journal of Cell Biology, Vol. 219, Núm. 9

  2. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 343-357

  2. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery

    Cancer Letters, Vol. 453, pp. 21-33

  3. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects

    American Journal of Respiratory and Critical Care Medicine, Vol. 197, Núm. 9, pp. 1164-1176

  2. Complement C4d-specific antibodies for the diagnosis of lung cancer

    Oncotarget, Vol. 9, Núm. 5, pp. 6346-6355

2017

  1. A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis

    Cancer Discovery, Vol. 7, Núm. 7, pp. 694-703

2016

  1. A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer

    Molecular Oncology, Vol. 10, Núm. 9, pp. 1437-1449

  2. Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. 524-536

2015

  1. Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma

    Oral Diseases, Vol. 21, Núm. 7, pp. 899-904

  2. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer

    PLoS ONE, Vol. 10, Núm. 3

2014

  1. Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

    EMBO Molecular Medicine, Vol. 6, Núm. 4, pp. 539-550

  2. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations

    International Journal of Cancer, Vol. 135, Núm. 11, pp. 2516-2527